270 related articles for article (PubMed ID: 22190384)
1. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
Antico Arciuch VG; Russo MA; Dima M; Kang KS; Dasrath F; Liao XH; Refetoff S; Montagna C; Di Cristofano A
Oncotarget; 2011 Dec; 2(12):1109-26. PubMed ID: 22190384
[TBL] [Abstract][Full Text] [Related]
2. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
3. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
4. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
5. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
6. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma.
Bellelli R; Castellone MD; Garcia-Rostan G; Ugolini C; Nucera C; Sadow PM; Nappi TC; Salerno P; Cantisani MC; Basolo F; Gago TA; Salvatore G; Santoro M
Endocr Relat Cancer; 2012 Oct; 19(5):695-710. PubMed ID: 22919068
[TBL] [Abstract][Full Text] [Related]
7. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
8. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Antico-Arciuch VG; Dima M; Liao XH; Refetoff S; Di Cristofano A
Oncogene; 2010 Oct; 29(42):5678-86. PubMed ID: 20676139
[TBL] [Abstract][Full Text] [Related]
10. Modeling anaplastic thyroid carcinoma in the mouse.
Champa D; Di Cristofano A
Horm Cancer; 2015 Feb; 6(1):37-44. PubMed ID: 25420535
[TBL] [Abstract][Full Text] [Related]
11. PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.
Chiappetta G; Valentino T; Vitiello M; Pasquinelli R; Monaco M; Palma G; Sepe R; Luciano A; Pallante P; Palmieri D; Aiello C; Rea D; Losito SN; Arra C; Fusco A; Fedele M
Oncotarget; 2015 Mar; 6(7):5310-23. PubMed ID: 25595894
[TBL] [Abstract][Full Text] [Related]
12. SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Zhu X; Kim DW; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jul; 23(7):521-33. PubMed ID: 27267120
[TBL] [Abstract][Full Text] [Related]
13. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
14. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.
Pringle DR; Vasko VV; Yu L; Manchanda PK; Lee AA; Zhang X; Kirschner JM; Parlow AF; Saji M; Jarjoura D; Ringel MD; La Perle KM; Kirschner LS
J Clin Endocrinol Metab; 2014 May; 99(5):E804-12. PubMed ID: 24512487
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
Ramírez-Moya J; Wert-Lamas L; Santisteban P
Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
[TBL] [Abstract][Full Text] [Related]
16. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation.
Zhong Z; Hu Z; Jiang Y; Sun R; Chen X; Chu H; Zeng M; Sun C
Oncotarget; 2016 Sep; 7(37):59652-59663. PubMed ID: 27487122
[TBL] [Abstract][Full Text] [Related]
18. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.
La Perle KM; Jhiang SM; Capen CC
Am J Pathol; 2000 Aug; 157(2):671-7. PubMed ID: 10934169
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
